ADIM develops custom 3D simulations for employee training, product demonstrations, and customer engagement, utilizing immersive technology to enhance learning and interaction. Their solutions provide measurable improvements in performance and engagement, addressing the need for effective training and communication in various industries.

AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using proprietary ²¹²Pb production technology to treat various cancers, including prostate and pancreatic. This approach aims to enhance patient survival and quality of life by delivering precise radiation to tumor cells while minimizing damage to surrounding healthy tissue.

This company develops a minimally invasive surgical device that uses photodynamic therapy to treat aggressive brain tumors. Their device delivers light to cancer cells exposed to a photosensitizer, offering patients a less invasive alternative to traditional brain surgery.

The startup develops targeted protein degradation therapeutics that utilize novel mechanisms to modulate the degradation of disease-related proteins. This approach aims to enhance therapeutic efficacy for a range of diseases by precisely regulating protein abundance linked to disease progression.

Artios Pharma develops oral small‑molecule inhibitors that target DNA damage response pathways in solid tumors, using its DcoDeR platform to align drugs with biomarker‑defined patient groups. Its lead ATR inhibitor alnodesertib, which has FDA Fast Track status for ATM‑deficient colorectal cancer, is intended to boost low‑dose chemotherapy, while the Polθ inhibitor ART6043 blocks micro‑homology‑mediated end joining and is being evaluated alone and with PARP inhibitors. The company provides combination‑ready, first‑in‑class DDR agents for oncology clinicians and pharmaceutical partners.

AstronauTx is developing targeted therapeutics to restore the functionality of astrocytes, which are critical for maintaining brain health. This approach aims to correct disrupted brain physiology associated with neurodegenerative diseases, potentially improving patient outcomes.

AviadoBio develops gene therapies utilizing a neuroanatomy-led approach to deliver treatments directly to the central nervous system for patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company addresses the lack of effective therapies for these neurodegenerative disorders by maximizing therapeutic potential to potentially halt or reverse disease progression.

Bicycle Therapeutics creates fully synthetic, bi‑cyclic peptide molecules that combine the high affinity of biologics with drug‑like pharmacokinetics, enabling precise targeting of protein‑protein interactions that are difficult for traditional small molecules or antibodies. Their platform delivers rapid tissue penetration, renal clearance, and flexible conjugation to payloads, supporting targeted drug conjugates and immune agonists for solid‑tumor oncology and a range of non‑oncology indications. The company partners with pharma, biotech, and academic groups to develop novel therapeutics for high‑unmet‑need disease targets.

BioAge provides a cloud‑based platform that generates multi‑omics biomarkers to quantify an individual’s biological age and predict health‑span trajectories. The service integrates genomics, transcriptomics, proteomics and metabolomics data with machine‑learning models, delivering calibrated age scores via a HIPAA‑compliant API and web dashboard for use by clinicians and pharmaceutical trial teams to personalize interventions and stratify study cohorts.

Brixton Biosciences is developing Neural Ice™, a therapeutic injection designed to provide three months or more of pain relief for patients suffering from chronic and acute pain. This investigational treatment, developed at Massachusetts General Hospital, aims to address the significant unmet clinical need for effective pain management solutions.

Cerevance utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify novel therapeutic targets for neurological diseases, including Parkinson's and Alzheimer's. The company develops cell type-specific therapies aimed at addressing the unmet medical needs associated with neurodegenerative and psychiatric disorders.

This platform provides a digital space for users to upload photos, videos, and audio files to create 3D memorials for loved ones. By creating an immersive experience, the platform helps individuals preserve memories and cope with grief.

Draig Therapeutics develops novel neuromodulators targeting Glutamate and GABA systems to restore synaptic balance in the central nervous system. Their pipeline of small molecules, including AMPA receptor PAMs and GABA A receptor NAMs/PAMs, aims to provide improved efficacy and tolerability for neuropsychiatric disorders like Major Depressive Disorder.

EBT develops neuromodulation technologies that target the Saphenous nerve to treat pelvic health disorders, beginning with overactive bladder. By leveraging the nerve’s role in pelvic function, the company aims to move neuromodulation from a last‑line option to a primary therapy in patient care pathways.

E INC enhances the automotive purchasing process by providing a digital platform that streamlines wholesale and retail transactions through advanced technology and data analytics. This approach addresses inefficiencies in the automotive ecosystem, enabling faster and more flexible business operations for dealers and consumers.

Ema utilizes a Generative Workflow Engine™ and a library of AI agents to automate complex workflows in HR, customer support, and data management, enhancing productivity across various enterprise roles. By integrating with hundreds of applications and employing a proprietary EmaFusion™ model, Ema ensures data accuracy and compliance while reducing operational costs.

The startup develops immunotherapy technologies that utilize tumor-specific antigens derived from endogenous retroviral DNA sequences to enhance cancer treatment efficacy. This approach enables hospitals to accurately assess tumor specificity and immunogenic potential, improving cancer monitoring and management.

GetFocus provides an AI platform for R&D leaders to scout emerging technologies and map the intellectual property landscape. The platform uses technology improvement rates to predict which innovations will succeed, enabling confident technology investment decisions. This foresight allows organizations to de-risk their R&D roadmaps and accelerate innovation timelines from months to days.

Heal is a nonprofit ecommerce platform that utilizes experience-based peer support to help individuals with mental illness reconnect with their passions through creative expression. By empowering emerging artists to showcase their work, Heal reinvests 100% of its profits into community-building initiatives that foster meaningful connections.

Lita is a Teammate-On-Demand platform that connects gamers with compatible players based on their preferred games and skill levels, facilitating collaborative gameplay and social interaction. The platform addresses the challenge of finding suitable teammates in the gaming community, enhancing the overall gaming experience in Southeast Asia and East Asia.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Octo provides a unified fintech platform centered around a digital card for managing personal finances in Egypt. Users can receive direct deposits, make purchases online and in-store, and manage everyday bill payments through a single mobile application. The service facilitates instant, zero-fee peer-to-peer money transfers while maintaining security compliance with CBE and PCI-DSS standards.

Perfuze is developing a superbore aspiration catheter designed for efficient access to occluded brain arteries during acute ischemic stroke treatment, enhancing the potential for complete clot removal. This technology addresses the significant challenge of achieving positive clinical outcomes, as less than 50% of stroke patients currently benefit from existing therapies.

Develops engineered regulatory T cells (Tregs) to restore immune tolerance in patients with severe autoimmune, inflammatory, or transplant-related diseases. By rebalancing the immune system, these therapies aim to prevent tissue damage, chronic inflammation, and graft rejection, offering a potential long-term solution for conditions lacking effective treatments.